top of page

Revolutionizing AMD Therapies: ANU and VivaZome's Transformative Collaboration.

CRC-P Partners from VivaZome Therapeutics, The Australian National University, The University of Queensland, La Trobe University, SeerPharma and Cytiva

Clear Vision Research (CVR), a leading research group in retinal diseases at the Australian National University (ANU), is proud to showcase a pioneering industry partnership with VivaZome Therapeutics Pty Ltd (VivaZome), an organisation focused on developing and commercialising Extracellular Vesicle (EV)-based therapies for debilitating disorders. This strategic collaboration marks a significant milestone in the pursuit of innovative solutions for age-related macular degeneration (AMD) using EVs.

Fostered through the strategic efforts of the Business Development team at the ANU, this partnership is underpinned by a shared mission to advance scientific understanding and develop transformative therapies for AMD. Both organizations are committed to pushing the boundaries of research and technology to address the complex challenges posed by age-related macular degeneration.

The Cooperative Research Centres Projects (CRC-P) Grant obtained by VivaZome with CVR as one of the partners, along with The University of Queensland, La Trobe University, SeerPharma and Cytiva, provides the opportunity to produce viable EV-based therapeutics.

Clear Vision Research and VivaZome look forward to the journey ahead and the positive impact this collaboration will have on individuals affected by age-related macular degeneration.

For a better understanding of this collaboration, we invite you to view the video from ANU media below:


bottom of page